Stock Research for CERE

CERE

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

CERE Stock Chart & Research Data

The CERE chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the CERE chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


CERE Due diligence Resources & Stock Charts

The CERE stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View CERE Detailed Price Forecast - CNN Money CNN View CERE Detailed Summary - Google Finance
Yahoo View CERE Detailed Summary - Yahoo! Finance Zacks View CERE Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View CERE Trends & Analysis - Trade-Ideas Barrons View CERE Major Holders - Barrons
NASDAQ View CERE Call Transcripts - NASDAQ Seeking View CERE Breaking News & Analysis - Seeking Alpha
Spotlight View CERE Annual Report - CompanySpotlight.com OTC Report View CERE OTC Short Report - OTCShortReport.com
TradeKing View CERE Fundamentals - TradeKing Charts View CERE SEC Filings - Bar Chart
WSJ View Historical Prices for CERE - The WSJ Morningstar View Performance/Total Return for CERE - Morningstar
MarketWatch View the Analyst Estimates for CERE - MarketWatch CNBC View the Earnings History for CERE - CNBC
StockMarketWatch View the CERE Earnings - StockMarketWatch MacroAxis View CERE Buy or Sell Recommendations - MacroAxis
Bullish View the CERE Bullish Patterns - American Bulls Short Pains View CERE Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View CERE Stock Mentions - StockTwits PennyStocks View CERE Stock Mentions - PennyStockTweets
Twitter View CERE Stock Mentions - Twitter Invest Hub View CERE Investment Forum News - Investor Hub
Yahoo View CERE Stock Mentions - Yahoo! Message Board Seeking Alpha View CERE Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for CERE - SECform4.com Insider Cow View Insider Transactions for CERE - Insider Cow
CNBC View CERE Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for CERE - OTC Markets
Yahoo View Insider Transactions for CERE - Yahoo! Finance NASDAQ View Institutional Holdings for CERE - NASDAQ


Stock Charts

FinViz View CERE Stock Insight & Charts - FinViz.com StockCharts View CERE Investment Charts - StockCharts.com
BarChart View CERE Stock Overview & Charts - BarChart Trading View View CERE User Generated Charts - Trading View




Latest Financial News for CERE


Heard on the Street: AbbVie’s Bet on a Neuroscience Drug Maker Just Got Better
Posted on Thursday April 18, 2024

AbbVie’s acquisition of neuroscience biotech Cerevel Therapeutics hasn’t closed yet. Notably, when AbbVie announced the $8.7 billion acquisition of Cerevel back in December, the main focus of the deal was the experimental schizophrenia drug Emraclidine, part of a new class of medications that target the muscarinic receptor. Late last year, Bristol Myers Squibb also announced its entry into the field, buying Karuna Therapeutics for $14 billion. The Food and Drug Administration is reviewing Karuna’s drug for the treatment of schizophrenia.


Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease
Posted on Thursday April 18, 2024

Tavapadon met the primary endpoint in the pivotal Phase 3 TEMPO-3 adjunctive trial, demonstrating a statistically significant increase in total “on” time without troublesome dyskinesia compared with placebo over 27 weeks Results demonstrate tavapadon’s potential to provide the right balance of motor control, safety and tolerability for people living with Parkinson’s disease Additional data from the trial will be presented at a future medical meeting; results from the tavapadon Phase 3 monotherap


AbbVie acquiring Cerevel Therapeutics in $8.7B deal
Posted on Thursday December 07, 2023

AbbVie (ABBV) announced it is acquiring neuroscience drug developer Cerevel Therapeutics (CERE) for $45.00 per share, putting the deal value at about $8.7 billion. AbbVie Chairman and CEO Richard Gonzalez said in the announcement that the combined portfolios will present a "significant growth opportunity well into the next decade." The deal comes about a week after AbbVie announced it was acquiring cancer drugmaker ImmunoGen (IMGN) for just over $10 billion. Yahoo Finance Healthcare Reporter Anjalee Khemlani breaks down the deal.  For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.


AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline
Posted on Wednesday December 06, 2023

AbbVie Inc. (NYSE: ABBV) and Cerevel Therapeutics (NASDAQ: CERE) today announced a definitive agreement under which AbbVie will acquire Cerevel Therapeutics and its robust neuroscience pipeline of multiple clinical-stage and preclinical candidates with potential across several diseases including schizophrenia, Parkinson's disease (PD), and mood disorders. The acquisition complements AbbVie's neuroscience portfolio, adding a wide range of potentially best-in-class assets that may transform standa


Stock Market & Investing Books

Enter a stock symbol to view the stock details.